China
Africa
Explore chapters and articles related to this topic
Phytonanotechnology
Published in Namrita Lall, Medicinal Plants for Cosmetics, Health and Diseases, 2022
Tafadzwa J. Chiome, Asha Srinivasan
Docetaxel is a well-known semi-synthetic poorly soluble taxane, which is being used in the treatment of breast, lung, oral and prostate cancers. The commercial form of Taxotere is formulated using high concentrations of Tween 80, which is linked to severe side effects like fluid retention, hypersensitivity reaction, mouth sores, hair loss, peripheral neuropathy and nausea (Immordino et al., 2003). Such a formulation resulted in lack of compatibility with poly-vinyl chloride administration sets. As a strategy to overcome multiple drug resistance during the treatment of breast cancer, docetaxel-loaded poly(ε-caprolactone)/Pluronic F68 nanoparticles was shown to be effective when used in docetaxel-resistant human breast cancer cell lines (Harush-Frenkel et al., 2008).
Antineoplastic Drugs during Pregnancy
Published in “Bert” Bertis Britt Little, Drugs and Pregnancy, 2022
The most difficult consideration in cancer treatment during pregnancy is optimal regimen formulation. The optimal regimen must include maternal and fetal effects of: (1) diagnostic tests, (2) surgical procedures, (3) radiotherapy, and (4) chemotherapy (Box 7.1). Limited data indicate the pregnant pharmacokinetics of certain antineoplastics (docetaxel, paclitaxel, doxorubicin, epirubicin) do not differ from non-pregnant adults (Janssen et al., 2021b).
Chemotherapy in pregnancy
Published in Hung N. Winn, Frank A. Chervenak, Roberto Romero, Clinical Maternal-Fetal Medicine Online, 2021
In rabbit and rat studies, fetal exposure to both docetaxel and paclitaxel have been associated with an increase in intrauterine deaths, increased fetal resorption, reduced fetal weight, and delayed ossification. Human studies have been limited to a scant number of case reports. In one report, docetaxel, cisplatin, and gemcitabine were given to a patient in the first and second trimesters of an unrecognized pregnancy (38). A healthy infant was delivered by cesarean section at 33 weeks, without congenital malformations. Sood et al. reported on the use of paclitaxel and cisplatin in a patient diagnosed with stage IIIC ovarian cancer at 27 weeks. After surgical debulking, she was given three cycles of chemotherapy prior to delivery. The child was 30 months of age, at the time of the publication, without any known abnormalities or developmental delays (24). Morris et al. reported on a patient with recurrent metastatic breast cancer diagnosed at 29 weeks of gestation. She received a total of six cycles of weekly paclitaxel and delivered a normal infant by elective cesarean section at 38 weeks (39). Additionally, a normal infant was delivered after three 21-day cycles of docetaxel given to a patient diagnosed with recurrent breast cancer at 15 weeks of gestation (13). Other reports have further confirmed that taxanes can be used safely in the second and third trimesters of pregnancy without significant risk of fetal malformations (14,40,41).
The Association Between Taxane Use and Lacrimal Disorders
Published in Current Eye Research, 2023
Gerald McGwin, Tucker Contorno, Matthew G. Vicinanzo, Cynthia Owsley
Reports of lacrimal disorders associated with docetaxel therapy began to appear in the literature soon after its approval in 1995.7 Since these early reports, studies have consistently reported the occurrence of excessive lacrimation with an incidence as high as >80%.4 The incidence does not appear to be associated with the underlying reason for use as it has been observed in patients receiving docetaxel for the treatment of breast, lung, ovarian cancer, among others. Additionally, a sensitivity analysis indicated that the associations were consistent when limited to indications for breast cancer, who may experience changes in estrogen activity which may lead to epiphora via effects directly on the ocular surface or on the meibomian glands, or via other mechanisms.9 This enhances the interpretation that the observed results are due to the medication, rather than indications for its use. Those patients receiving a frequent (e.g. once per week) or an extended treatment (e.g. six months) schedule appear to be at greatest risk of epiphora.4 While surgery is successful in resolving this condition, outcomes worsen with delays in seeking care, underscoring the importance of patient and provider education. For certain indications and patients (e.g. elderly), paclitaxel has been shown to have similar efficacy as docetaxel with less toxicity and better tolerability.10
An up-to-date evaluation of abiraterone for the treatment of prostate cancer
Published in Expert Opinion on Pharmacotherapy, 2021
Jason Shpilsky, Julia Stevens, Glenn Bubley
Abiraterone is an effective and well-tolerated addition to ADT in both mCSPC and mCRPC. In mCSPC, docetaxel has primarily demonstrated a benefit in high-volume disease whereas abiraterone has demonstrated a benefit in a general mCSPC population [30,40]. Furthermore, docetaxel is associated with fatigue, neuropathy, and cytopenias which may preclude use in an elderly population. Intravenous docetaxel is less convenient as compared to an oral therapy. When considering apalutamide or enzalutamide, providers must consider the risks for seizures, falls, and fatigue. Although there are no head-to-head studies comparing efficacy of abiraterone to the novel anti-androgens in this setting, sequencing data with abiraterone versus enzalutamide for mCRPC are instructive. The crossover trial by Khalaf and colleagues indicated that using abiraterone before enzalutamide may be beneficial due to low abiraterone response after enzalutamide failure [31]. These results could be extrapolated to use of abiraterone for mCSPC to allow subsequent use of enzalutamide for mCRPC.
Docetaxel-induced acute myositis: a case report with review of literature
Published in Journal of Chemotherapy, 2021
Sariya Wongsaengsak, Miguel Quirch, Somedeb Ball, Anita Sultan, Nusrat Jahan, Mohamed Elmassry, Shabnam Rehman
Docetaxel is a medication in the Taxane group. Docetaxel is an antimicrotubule agent that inhibits the reorganization of the microtubule network that is needed for mitosis, thereby leading to cancer cell apoptosis.1 Docetaxel was first approved by the Food and Drug Administration (FDA) in 1996 as a second-line treatment of locally advanced and metastatic breast cancer based on the positive results from clinical trials which showed that it was a highly effective antineoplastic agent for breast cancer.2 Since then, its indications have expanded to the treatment of many other solid tumors such as non small cell lung cancer, prostate cancer, gastric adenocarcinoma, and squamous cell carcinoma of head and neck.3 The well-established side effects of docetaxel are myelosuppression, severe neutropenia, peripheral neuropathy, fluid retention, and asthenia.1,2 The most commonly reported musculoskeletal adverse event is myalgia and joint pain. A few studies reported that 78%-87% of patients who have been exposed to taxanes experienced mild to moderate myalgia at some point in the course of treatment.1,4,5 Unfortunately, severe acute myositis remains an unusual complication. We report a case of acute myositis related to docetaxel in a patient with breast cancer.